Product Name
AIPL1, siRNA
Full Product Name
AIPL1 siRNA (Human)
Product Synonym Names
AIPL2; Aryl-hydrocarbon-interacting protein-like 1
Product Gene Name
AIPL1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9NZN9
Specificity
AIPL1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human AIPL1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of AIPL1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
AIPL1 sirna
siRNA to inhibit AIPL1 expression using RNA interference
Applications Tested/Suitable for AIPL1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for AIPL1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001028226.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001033054.2
[Other Products]
UniProt Primary Accession #
Q9NZN9
[Other Products]
UniProt Secondary Accession #
Q659W3; Q659W4; Q6ZZB6; Q8N6A0; Q9H873; Q9NS10; D3DTM4[Other Products]
UniProt Related Accession #
Q9NZN9[Other Products]
Molecular Weight
40,901 Da
NCBI Official Full Name
aryl-hydrocarbon-interacting protein-like 1 isoform 2
NCBI Official Synonym Full Names
aryl hydrocarbon receptor interacting protein-like 1
NCBI Official Symbol
AIPL1 [Similar Products]
NCBI Official Synonym Symbols
LCA4; AIPL2
[Similar Products]
NCBI Protein Information
aryl-hydrocarbon-interacting protein-like 1
UniProt Protein Name
Aryl-hydrocarbon-interacting protein-like 1
Protein Family
Aryl-hydrocarbon-interacting protein
UniProt Gene Name
AIPL1 [Similar Products]
UniProt Synonym Gene Names
AIPL2 [Similar Products]
UniProt Entry Name
AIPL1_HUMAN
NCBI Summary for AIPL1
Leber congenital amaurosis (LCA) is the most severe inherited retinopathy with the earliest age of onset and accounts for at least 5% of all inherited retinal diseases. Affected individuals are diagnosed at birth or in the first few months of life with nystagmus, severely impaired vision or blindness and an abnormal or flat electroretinogram. The photoreceptor/pineal-expressed gene, AIPL1, encoding aryl-hydrocarbon interacting protein-like 1, is located within the LCA4 candidate region. The encoded protein contains three tetratricopeptide motifs, consistent with chaperone or nuclear transport activity. Mutations in this gene may cause approximately 20% of recessive LCA. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]
UniProt Comments for AIPL1
AIPL1: May be important in protein trafficking and/or protein folding and stabilization. Defects in AIPL1 are the cause of Leber congenital amaurosis type 4 (LCA4). LCA designates a clinically and genetically heterogeneous group of childhood retinal degenerations, generally inherited in an autosomal recessive manner. Affected infants have little or no retinal photoreceptor function as tested by electroretinography. LCA represents the most common genetic cause of congenital visual impairment in infants and children. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Chaperone; Apoptosis
Chromosomal Location of Human Ortholog: 17p13.1
Cellular Component: photoreceptor inner segment; cytoplasm; nucleus
Molecular Function: farnesylated protein binding; protein binding; unfolded protein binding
Biological Process: retinal homeostasis; phototransduction, visible light; protein farnesylation; visual perception; protein folding; regulation of cGMP metabolic process; negative regulation of apoptosis
Disease: Leber Congenital Amaurosis 4; Retinitis Pigmentosa
Research Articles on AIPL1
1. The authors established a transgenic mouse model for cone-rod dystrophy carrying human AIPL1 gene with deletion in the C-terminal proline-rich region.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
